Jiang, Qian <br/><br/>
Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.  [electronic resource] 

 -  Medicine  Jun 2019 
 - e16065 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1536-5964 
<br/><br/><label>Standard No.: </label>10.1097/MD.0000000000016065  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--adverse effects<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Disease Progression<br/>Docetaxel--adverse effects<br/>Drug Therapy, Combination<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Preliminary Data<br/>Prospective Studies<br/>Protein Kinase Inhibitors--adverse effects<br/>Pyridines--adverse effects<br/>Retreatment<br/>Survival Analysis<br/>Treatment Outcome<br/>Tubulin Modulators--adverse effects